Table S3.
Additional baseline patient characteristics by matched treatment cohort
| Characteristic | Initiation sample
|
Step-up sample
|
||||
|---|---|---|---|---|---|---|
| Extrafine BDP (n=334) |
Fluticasone (n=334) |
P-valuea | Extrafine BDP (n=189) |
Fluticasone (n=189) |
P-valuea | |
| Timing of COPD diagnosis code in database, n (%) | ||||||
| <3 yr before index date | 52 (15.6) | 63 (18.9) | 0.13 | 50 (26.5) | 57 (30.2) | 0.17 |
| 6 mo to 3 yr before index date | 82 (24.6) | 81 (24.3) | 32 (16.9) | 43 (22.8) | ||
| At or <6 mo before index date | 102 (30.5) | 117 (35.0) | 33 (17.5) | 28 (14.8) | ||
| <3 yr after index date | 66 (19.8) | 40 (12.0) | 41 (21.7) | 31 (16.4) | ||
| ≥3 yr after index date | 32 (9.6) | 33 (9.9) | 33 (17.5) | 30 (15.9) | ||
| BMI category, n (%)b | ||||||
| Underweight (BMI <18.5 kg/m2) | 14 (4.2) | 15 (4.6) | 0.96 | 5 (2.7) | 6 (3.3) | 0.84 |
| Normal (BMI 18.5–<24.5 kg/m2) | 132 (39.9) | 125 (38.1) | 75 (40.5) | 78 (42.4) | ||
| Overweight (BMI 24.5–<30 kg/m2) | 115 (34.7) | 121 (36.9) | 67 (36.2) | 57 (31.0) | ||
| Obese (BMI ≥30 kg/m2) | 70 (21.1) | 67 (20.4) | 38 (20.5) | 43 (23.4) | ||
| ≥1 prescription in baseline year or at index date, n (%) | ||||||
| Beta blocker | 37 (11.1) | 35 (10.5) | 0.80 | 19 (10.1) | 9 (4.8) | 0.056 |
| NSAID | 134 (40.1) | 113 (33.8) | 0.082 | 81 (42.9) | 70 (37.0) | 0.26 |
| Paracetamol | 114 (34.1) | 123 (36.8) | 0.47 | 75 (39.7) | 72 (38.1) | 0.72 |
| Antidepressant | 47 (14.1) | 65 (19.5) | 0.049 | 35 (18.5) | 27 (14.3) | 0.11 |
| Daily SABA dose, median (IQR) | 219 (110–548) | 219 (110–548) | 0.77 | 384 (219–658) | 438 (219–767) | 0.22 |
| Daily SAMA dose, median (IQR) | 0 (0–55) | 11 (0–55) | 0.16 | 0 (0–44) | 0 (0–55) | 0.40 |
| Pneumonia diagnosis, confirmed, n (%) | 0 (0) | 3 (0.9) | n/a | 1 (0.5) | 0 (0) | n/a |
Notes:
a
Matched cohorts were compared using conditional logistic regression
b
recorded BMI data were available for 331 (99%) and 328 (98%) patients in extrafine beclomethasone and fluticasone initiation cohorts, respectively, and for 185 (98%) and 184 (97%) patients in extrafine beclomethasone and fluticasone step-up cohorts, respectively.
Abbreviations: BDP, beclomethasone dipropionate; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; n/a, not applicable; NSAID, nonsteroidal anti-inflammatory drug; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist; yr, years; mo, months.